Transarterial chemoembolization (TACE) is a type of treatment for liver cancer. It works by delivering chemotherapy drugs directly to the tumor and blocking its blood supply. Liver cancer occurs ...

PFS was based on RECICL (Response Evaluation Criteria in Cancer of the Liver) in the intention-to-treat (ITT) population. The 6-month PFS was 70.8% with TACE-CR and 31.5% with TACE alone.

To date, there is no evidence that TACE pre-liver transplantation or resection helps to expand current selection criteria for patients with HCC, nor results in less recurrence after surgery.

Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with ...

Hepatic failure: liver failure. Myositis: inflammation of the muscles TACE, according to the Cleveland Clinic, is a procedure that involves injecting a combination of cancer-fighting drugs and an ...

Terumo India introduces innovative ‘Occlusafe’ in liver cancer treatment: Shardul Nautiyal, Mumbai Saturday, March 15, 2025, 08:00 Hrs [IST] Terumo India Private Limited has t ...

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

“Compared with TACE, EBRT yields superior [local control] and [progression-free survival] with similar [overall survival] and should be considered a first-line approach when utilizing liver ...

the most common type of liver cancer, are eligible for embolisation therapy. Adding Imfinzi and bevacizumab to TACE resulted in a 23% reduction in PFS, with a median of 15 months for the test ...